IN BRIEF: Genflow launches new ophthalmology development programme
Genflow Biosciences PLC - London-based biotechnology firm, which has research facilities in Belgium - Launches new ophthalmology development programme, focused on advancing a novel gene therapy via its proprietary gene technology. The therapy will use a specially designed non-viral vector engineered for precise delivery of Genflow's SIRT6 to the eye. It is designed to counter ocular problems including several pathologies of the cornea and glaucoma. Read More